Connect with us
The Spanish pharma sector faced a downturn in the stock market in Q1 of 2024, with a collective market capitalization drop of 15.8% for six listed...
The European Medicines Agency (EMA) is close to authorizing UCB's new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...
Atrys Health reports 2023 losses of 45 million euros, nearly doubling from the previous year, despite a 27.3% increase in revenue to 202 million euros and...
Faes Farma forecasts a double-digit growth in Latin America and plans to expand its medical visit, animal nutrition, and health businesses. The Spanish pharmaceutical company aims...
Cure51 secured funding in a round led by Sofinnova Partners, joined by Hitachi Ventures, Xavier Niel, and others. The company aims to investigate molecular processes enabling...
Ysios Capital, specializing in biotech investments, will invest $157 million in Engrail Therapeutics, joining a syndicate led by F-Prime Capital. Engrail, founded in 2019, focuses on...
Europacific Growth Fund, legal owner of Grifols shares, lent over 100 million euros worth of shares, reducing its ownership from 3.4% to 3.2%. Capital Research and...
MDMA became famous in the 80s as a party drug under the names Ecstasy or Molly - complete with abuse, damage, and deaths. As a result,...
AstraZeneca Spain's president, Rick R. Suárez, announced a €1.3 billion investment in Catalonia until 2027, exceeding previous plans by €500 million. They aim to employ 2,000...